| 中文名稱 | 絲裂原活化蛋白激酶1/ERK 1/2抗體 |
| 別 名 | ERK 1/2; ERK 1; ERK 2; ERK-2; ERK1; ERK2; ERT1; ERT2; Extracellular signal regulated kinase 1; Extracellular signal regulated kinase 2; Extracellular signal-regulated kinase 2; HS44KDAP; HUMKER1A; Insulin stimulated MAP2 kinase; MAP kinase 1; MAP kinase 2; MAP kinase isoform p42; MAP kinase isoform p44; MAPK 1; MAPK 2; MAPK 3; MAPK1; MAPK2; MAPK3; MGC20180; Microtubule associated protein 2 kinase; Mitogen activated protein kinase 1; Mitogen activated protein kinase 2; Mitogen activated protein kinase 3; Mitogen-activated protein kinase 1; Mitogen-activated protein kinase 2; MK01_HUMAN; MK03_HUMAN; p38; p40; p41; p41mapk; p42 MAPK; p42-MAPK; p42MAPK; p44 ERK1; p44 MAPK; p44ERK1; p44MAPK; PRKM 1; PRKM 2; PRKM 3; PRKM1; PRKM2; PRKM3; Protein kinase mitogen activated 1; Protein kinase mitogen activated 2; Protein kinase mitogen activated 3; Protein tyrosine kinase ERK 2. |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 信號轉(zhuǎn)導(dǎo) 干細(xì)胞 細(xì)胞凋亡 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 細(xì)胞骨架 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, Rat, (predicted: Chicken, Dog, Pig, Cow, Horse, Rabbit, ) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1μg/Test IF=1:100-500 （石蠟切片需做抗原修復(fù)） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 42kDa |
| 細(xì)胞定位 | 細(xì)胞核 細(xì)胞漿 細(xì)胞膜 細(xì)胞外基質(zhì) |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human ERK2:301-358/358 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | The protein encoded by this gene is a member of the MAPkinase family. MAP kinases, also known as extracellularsignal-regulated kinases (ERKs), act in a signaling cascade thatregulates various cellular processes such as proliferation,differentiation, and cell cycle progression in response to avariety of extracellular signals. This kinase is activated byupstream kinases, resulting in its translocation to the nucleuswhere it phosphorylates nuclear targets. Alternatively splicedtranscript variants encoding different protein isoforms have beendescribed. [provided by RefSeq, Jul 2008]. Function: Serine/threonine kinase which acts as an essentialcomponent of the MAP kinase signal transduction pathway. MAPK1/ERK2and MAPK3/ERK1 are the 2 MAPKs which play an important role in theMAPK/ERK cascade. They participate also in a signaling cascadeinitiated by activated KIT and KITLG/SCF. Depending on the cellularcontext, the MAPK/ERK cascade mediates diverse biological functionssuch as cell growth, adhesion, survival and differentiation throughthe regulation of transcription, translation, cytoskeletalrearrangements. The MAPK/ERK cascade plays also a role ininitiation and regulation of meiosis, mitosis, and postmitoticfunctions in differentiated cells by phosphorylating a number oftranscription factors. About 160 substrates have already beendiscovered for ERKs. Many of these substrates are localized in thenucleus, and seem to participate in the regulation of transcriptionupon stimulation. However, other substrates are found in thecytosol as well as in other cellular organelles, and those areresponsible for processes such as translation, mitosis andapoptosis. Moreover, the MAPK/ERK cascade is also involved in theregulation of the endosomal dynamics, including lysosome processingand endosome cycling through the perinuclear recycling compartment(PNRC); as well as in the fragmentation of the Golgi apparatusduring mitosis. The substrates include transcription factors (suchas ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements(such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1),regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3,MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and avariety of other signaling-related molecules (like ARHGEF2, DCC,FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1,RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1,MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) andphosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are othersubstrates which enable the propagation the MAPK/ERK signal toadditional cytosolic and nuclear targets, thereby extending thespecificity of the cascade. Mediates phosphorylation of TPR inrespons to EGF stimulation. May play a role in the spindle assemblycheckpoint. Phosphorylates PML and promotes its interaction withPIN1, leading to PML degradation (By similarity). Acts as a transcriptional repressor. Binds to a[GC]AAA[GC] consensus sequence. Repress the expression ofinterferon gamma-induced genes. Seems to bind to the promoter ofCCL5, DMP1, IFIH1, IFITM1, IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 andSTAT1. Transcriptional activity is independent of kinase activity. Subunit: Binds both upstream activators and downstream substratesin multimolecular complexes. Interacts with ADAM15, ARHGEF2, ARRB2,DAPK1 (via death domain), HSF4, IER3, IPO7, DUSP6, NISCH, SGK1, andisoform 1 of NEK2. Interacts (via phosphorylated form) with TPR(via C-terminus region and phosphorylated form); the interactionrequires dimerization of MAPK1/ERK2 and increases following EGFstimulation. Interacts (phosphorylated form) withCAV2 ('Tyr-19'-phosphorylated form); the interaction, promoted byinsulin, leads to nuclear location and MAPK1 activation. Interacts with DCC. Interacts withMORG1, PEA15 and MKNK2. MKNK2 isoform 1 binding prevents fromdephosphorylation and inactivation. The phosphorylated forminteracts with PML. Subcellular Location: Cytoplasm, cytoskeleton, spindle. Nucleus. Cytoplasm, cytoskeleton, centrosome. Cytoplasm. Note=Associated with the spindle duringprometaphase and metaphase. PEA15-binding andphosphorylated DAPK1 promote its cytoplasmic retention.Phosphorylation at Ser-244 and Ser-246 as well asautophosphorylation at Thr-188 promote nuclear localization. Tissue Specificity: Widely expressed. Post-translational modifications: Dually phosphorylated on Thr-183 and Tyr-185, which activatesthe enzyme. Ligand-activated ALK induces tyrosine phosphorylation. Dephosphorylated by PTPRJ at Tyr-185. Phosphorylated upon FLT3 and KIT signaling. Similarity: Belongs to the protein kinase superfamily. CMGCSer/Thr protein kinase family. MAP kinase subfamily. Contains 1 protein kinase domain. SWISS: P27361 Gene ID: 5595 Database links: Entrez Gene: 5594 Human Entrez Gene: 5595 Human Entrez Gene: 26413 Mouse Entrez Gene: 26417 Mouse Entrez Gene: 116590 Rat Entrez Gene: 50689 Rat Entrez Gene: 327672 Cow Omim: 176948 Human Omim: 601795 Human SwissProt: P46196 Cow SwissProt: P27361 Human SwissProt: P28482 Human SwissProt: P63085 Mouse SwissProt: Q63844 Mouse SwissProt: P21708 Rat SwissProt: P63086 Rat Unigene: 431850 Human Unigene: 861 Human Unigene: 196581 Mouse Unigene: 8385 Mouse Unigene: 2592 Rat Unigene: 34914 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 激酶和磷酸酶（Kinases and Phosphatases） 絲裂原活化蛋白激酶-ERK（Mitogen-activated protein kinase 1, MAPK-1）是一組可以被多種細(xì)胞外信號即獲得蛋白絲/蘇氨酸激酶，處于胞漿信號傳導(dǎo)通路的終末位置，活化后轉(zhuǎn)位到核內(nèi)，作用于核內(nèi)轉(zhuǎn)錄因子，調(diào)節(jié)基因表達(dá)。它主要參與生長因子、激素、細(xì)胞因子、應(yīng)激等各種刺激下細(xì)胞的反應(yīng)、細(xì)胞的生長、分化過程。 蛋白分子量：42kDa。 經(jīng)研究證實(shí)，MAPK信號轉(zhuǎn)導(dǎo)通路存在于大多數(shù)細(xì)胞內(nèi)，在將細(xì)胞外刺激信號轉(zhuǎn)導(dǎo)至細(xì)胞及其核內(nèi)，并引起細(xì)胞生物學(xué)反應(yīng)（如細(xì)胞增殖、分化、轉(zhuǎn)化及凋亡等）的過程中具有至關(guān)重要的作用。研究表明，MAPK信號轉(zhuǎn)導(dǎo)通路在細(xì)胞內(nèi)具有生物進(jìn)化的高度保守性，在低等原核細(xì)胞和高等哺乳類細(xì)胞內(nèi)，目前均已發(fā)現(xiàn)存在著多條并行的MAPK信號通路，不同的細(xì)胞外刺激可使用不同的MAPK信號通路，通過其相互調(diào)控而介導(dǎo)不同的細(xì)胞生物學(xué)反應(yīng)。 |
| 產(chǎn)品圖片 | Sample: Brain (Rat) Lysate at 30 ug Heart (Rat) lysate at 30 ug Primary: Anti- ERK2/MAPK1 (bs-0022R) at 1/200 dilution Secondary: HRP conjugated Goat-Anti-rabbit IgG (bs-0295G-HRP) at 1/3000 dilution Predicted band size: 42 kD Observed band size: 42 kD  Sample:Lane 1: Cerebrum (Mouse) Lysate at 40 ug Lane 2: Cerebrum (Rat) Lysate at 40 ug Lane 3: Lymph node (Mouse) Lysate at 40 ug Lane 4: Lymph node (Rat) Lysate at 40 ug Primary: Anti-ERK1 + ERK2 (bs-0022R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 44/42 kD Observed band size: 40 kD  Sample:Lane 1: A431 (Human) Cell Lysate at 30 ug Lane 2: MCF-7 (Human) Cell Lysate at 30 ug Lane 3: Huvec (Human) Cell Lysate at 30 ug Primary: Anti-ERK1 + ERK2 (bs-0022R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 44/42 kD Observed band size: 42/40 kD  Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (ERK1 + ERK2) Polyclonal Antibody, Unconjugated (bs-0022R) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-ERK2/MAPK1 Polyclonal Antibody, Unconjugated(bs-0022R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining  Tissue/cell: Hela cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (ERK1 + ERK2) polyclonal Antibody, Unconjugated (bs-0022R) 1:100, 90 minutes at 37°C; followed by a FITC conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei. Blank control: Hep G2 cells (blue).Primary Antibody:Rabbit Anti-ERK1 + ERK2 antibody(bs-0022R), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG(orange) ,used under the same conditions ); Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA. Protocol The cells were fixed with 2% paraformaldehyde (10 min) , then permeabilized with 90% ice-cold methanol for 30 min on ice. Primary antibody (bs-0022R, 1μg /1x10^6 cells) were incubated for 30 min on the ice, followed by 1 X PBS containing 0.5% BSA + 1 0% goat serum (15 min) to block non-specific protein-protein interactions. Then the Goat Anti-rabbit IgG/PE antibody was added into the blocking buffer mentioned above to react with the primary antibody at 1/200 dilution for 30 min on ice. Acquisition of 20,000 events was performed. |
我要詢價
*聯(lián)系方式：
(可以是QQ、MSN、電子郵箱、電話等，您的聯(lián)系方式不會被公開)
*內(nèi)容：
